为了促进商业化,BioNxt获得了无针的MS药片全球专利. BioNxt secures global patents for needle-free MS drug films to boost commercialization.

生物Nxt解决方案公司已进入其语言下药物递送平台的商业化阶段,并得到了强大的全球专利组合支持. BioNxt Solutions Inc. has entered a commercialization phase for its sublingual drug delivery platform, bolstered by a robust global patent portfolio. 公司获得了欧洲和欧亚专利,覆盖多达39个国家. The company secured European and Eurasian patents covering up to 39 countries and is pursuing a U.S. fast-track patent filing. 这些专利保护了克拉迪宾用于多发性硬化和严重肌痛神经衰竭的治疗方法,旨在通过无针的溶解膜改善患者的结果. These patents protect the delivery of cladribine for multiple sclerosis and myasthenia gravis, aiming to improve patient outcomes through needle-free, dissolving films. 现在BioNxt正在寻求战略合作伙伴, 以获得许可并共同开发其技术. BioNxt is now seeking strategic partnerships to license and co-develop its technology.